Cumulative prevalence of venous thromboembolic events in ITP patients who underwent splenectomy compared with those who did not. Cumulative prevalence.

Slides:



Advertisements
Similar presentations
JAK2V617F mutation for the early diagnosis of Ph − myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis by Francesco Dentali,
Advertisements

DEFINING THE DURATION OF ANTICOAGULATION. HOW LONG TO TREAT A DVT?
BluntPenetrating Placebo rFVIIa Patients (%) n=20 n=8 n=9 n=4 P=0.03 P=0.068 Adapted from Rizoli S. Canadian Anesthesiologists’
Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,
Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated with Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
Recommendations for Catheter-to-Vein Ratio
Lako S, Daka A, Nurka T, Dedej T, Memishaj S
Comparison of three Observational Analytical strategies
UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER
From: Temporal Trends in Anesthesia-related Adverse Events in Cesarean Deliveries, New York State, 2003–2012 Anesthes. 2015;123(5): doi: /ALN
UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER
by Hugoline G. de Haan, Irene D. Bezemer, Carine J. M
Central venous line–related thrombosis in children: association with central venous line location and insertion technique by Christoph Male, Peter Chait,
by Nadine Martel, James Lee, and Philip S. Wells
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,
Daniel C. Thomas, MD, MPH, Brian N. Arnold, MD, Jessica R
Timothy A. Brighton, M. B. , B. S. , John W. Eikelboom, M. B. , B. S
The Burden of Hospital-Associated Venous Thromboembolism
by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa
Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura
Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.
Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology by Mary Cushman,
A Systematic Review On Different Prothrombin Complex Concentrate Strategies To Reverse Vitamin K Antagonist Therapy by Nakisa Khorsand, Hilde A.M. Kooistra,
Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,
Nonmyeloablative conditioning for relapsed follicular lymphoma
Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.
Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to.
by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu
Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.
Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism by Sabine Eichinger, Verena Schönauer, Ansgar Weltermann,
Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.
Studies reporting the incident rate for thrombosis per 1000 patient days. Studies reporting the incident rate for thrombosis per 1000 patient days. Dashed.
New Oral Anticoagulants and VTE Management
Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
Venous Thromboembolism with Chronic Liver Disease
Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study by Dirk.
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.
Primary testicular lymphoma
Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk.
by Jon E. Arnason, Federico Campigotto, Donna Neuberg, and James B
Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,
Deep venous thrombosis after repair of nonruptured abdominal aneurysm


How I treat cancer-associated venous thromboembolism
Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.
References: Anticoagulation should be continued 3-6 months for the treatment of VTE in cancer patients: 1. ASCO: Lyman GH, Bohlke K, Khorana AA, et al.
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study by Inger Lise Gade, Signe Juul Riddersholm, Ilse Christiansen,
Cohort Study.
Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.
Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.
Ted Wun, M. D. , Ann Brunson, M. S. , Theresa Keegan, Ph. D
Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis by Samuel Yamshon,
Ob/Gyn Journal Club Notes
Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis by Rasha Khatib, Maja Ludwikowska, Daniel.
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
Cumulative mortality risk in patients with 48-h blood urea nitrogen (BUN) levels of ≥8 mg/dl or
American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism by Wendy Lim, Grégoire Le.
Plots of average estimated and measured GFR vs
Two run charts showing the effects of Plan, Do, Study, Act cycles on 24-hour Electronic Patient Records venous thromboembolism (EPR VTE) risk assessment.
A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.
A fishbone diagram summarising factors contributing to urology inpatients not having a 24-hour Electronic Patient Records venous thromboembolism (EPR VTE)
Therapy of adult ITP before splenectomy.
Deep venous thrombosis after repair of nonruptured abdominal aneurysm
Cold agglutinin disease
Presentation transcript:

Cumulative prevalence of venous thromboembolic events in ITP patients who underwent splenectomy compared with those who did not. Cumulative prevalence of venous thromboembolic events in ITP patients who underwent splenectomy compared with those who did not. There is an increased rate of VTE in patients with ITP that underwent splenectomy vs those who did not; however, the absolute risk is low in both groups. We included population-based/administrative cohort studies (N = 5) and retrospective (N = 7) and prospective (N = 2) cohort studies that reported outcomes on at least 50 patients with ITP, with a median follow-up >3 months.22,55,68-72 For the splenectomy patients in particular, we included only studies that reported late (>3 months) VTE events to minimize selection bias from studies focusing on postoperative portal and splenic vein thrombosis. Time is calculated from date of splenectomy in the splenectomy group and date of enrollment in cohort for the nonsplenectomy group. When only median follow-up was provided, means were approximated as described by Wan et al.73 Some selection bias is possible because the patients that underwent splenectomy may have had more severe disease than the comparison group. Shruti Chaturvedi et al. Blood 2018;131:1172-1182 ©2018 by American Society of Hematology